Molecular Neuropharmacology, Department of Physiology, School of Medicine, Trinity College Dublin, Dublin, Ireland.
J Mol Neurosci. 2014 May;53(1):125-34. doi: 10.1007/s12031-013-0209-z. Epub 2013 Dec 21.
SNX8 is a PX-BAR domain sub-family of sorting nexins (SNXs), which is reported as a β-amyloid (Aβ) toxicity enhancer and associated with Alzheimer's disease. We have also described SNX8 as a novel activator of the sterol regulatory element binding protein (SREBP) transcription factor, a major regulator of cholesterol homeostasis. In that study, we have showed that SNX8 reduced an insulin-induced gene (INSIG)-dependent block of SREBP-mediated transcription. Here, for the first time, we investigated the expression and function of SNX8 within the CNS. We found that SNX8 was expressed within neurons, but not astrocytes or microglia, with neuronal localisation primarily in the soma. The protein levels of neuronal SNX8 were unchanged in the presence of moderately high cholesterol but were decreased by mevinolin (a cholesterol-lowering statin) and U18666a (which causes cholesterol to accumulate within the lysosome). To determine if SNX8 overexpression alters the levels of cholesterol, we engineered a GFP-SNX8 lentivirus. The overexpression of GFP-SNX8 had no effect on cholesterol in neurons under control conditions or in already strongly altered cholesterol conditions of mevinolin or U18666a. In contrast, in moderately high cholesterol, the overexpression of GFP-SNX8 caused redistribution of cholesterol within neurons creating a phenotype similar to U18666a treatment. Taken together, these data suggest that extreme changes in cholesterol reduce SNX8 expression and that overexpression of SNX8 exacerbates aberrant handling of neuronal cholesterol. This work further supports the role for SNX8 in regulating cholesterol levels, which could be important in understanding its role as an Aβ toxicity enhancer and its association with Alzheimer's disease.
SNX8 是分选连接蛋白(SNXs)的 PX-BAR 结构域亚家族,据报道其可增强 β-淀粉样蛋白(Aβ)毒性,并与阿尔茨海默病有关。我们还将 SNX8 描述为固醇调节元件结合蛋白(SREBP)转录因子的新型激活剂,后者是胆固醇稳态的主要调节剂。在该研究中,我们表明 SNX8 降低了胰岛素诱导基因(INSIG)对 SREBP 介导的转录的依赖性阻断。在这里,我们首次在中枢神经系统(CNS)中研究了 SNX8 的表达和功能。我们发现 SNX8 在神经元中表达,但在星形胶质细胞或小胶质细胞中不表达,神经元的定位主要在胞体。中等水平胆固醇存在时,神经元 SNX8 的蛋白水平不变,但被美伐他汀(一种降低胆固醇的他汀类药物)和 U18666a(导致胆固醇在溶酶体中积累)降低。为了确定 SNX8 过表达是否改变胆固醇水平,我们设计了 GFP-SNX8 慢病毒。在对照条件下,或在美伐他汀或 U18666a 已强烈改变胆固醇条件下,GFP-SNX8 的过表达对神经元中的胆固醇没有影响。相比之下,在中等水平胆固醇中,GFP-SNX8 的过表达导致胆固醇在神经元内重新分布,产生类似于 U18666a 处理的表型。总之,这些数据表明,胆固醇的剧烈变化会降低 SNX8 的表达,而过表达 SNX8 会加剧神经元胆固醇的异常处理。这项工作进一步支持了 SNX8 在调节胆固醇水平中的作用,这对于理解其作为 Aβ 毒性增强剂的作用及其与阿尔茨海默病的关联可能很重要。